The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling

BACKGROUND: During kidney fibrosis, a hallmark and promoter of CKD (regardless of the underlying renal disorder leading to CKD), the extracellular-regulated kinase 1/2 (ERK1/2) pathway, is activated and has been implicated in the detrimental differentiation and expansion of kidney fibroblasts. An ER...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Soc Nephrol
Auteurs principaux: Andrikopoulos, Petros, Kieswich, Julius, Pacheco, Sabrina, Nadarajah, Luxme, Harwood, Steven Michael, O'Riordan, Caroline E., Thiemermann, Christoph, Yaqoob, Muhammad M.
Format: Artigo
Langue:Inglês
Publié: American Society of Nephrology 2019
Sujets:
Basic Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6317609/
https://ncbi.nlm.nih.gov/pubmed/30530834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018020209
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires